Serrapeptase for Osteoarthritis
Verdict: Insufficient Evidence
Across 2 PubMed studies, the evidence for Serrapeptase in Osteoarthritis grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.
U ⚫ U Unverified Insufficient Evidence
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.43
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
77%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.427
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (2)L2 · primary research & systematic reviews
Serratiopeptidase: a systematic review of the existing evidence
Finding: Identified 24 clinical efficacy studies and 11 RCTs across mixed indications (mainly ENT, dental, post-surgical). Concluded the existing scientific evidence for serratiopeptidase is insufficient to support its use as an analgesic and health supplement; most studies graded as poor methodology (small samples, poorly defined enrollment/outcomes, unclear statistics, short duration). No dedicated osteoarthritis or joint-pain trial identified.
View on PubMed Serratiopeptidase: Insights into the therapeutic applications
Finding: Reviews proposed anti-inflammatory, antiedemic and fibrinolytic activity. States robust clinical evidence is lacking and that data on antiatherosclerotic activity, safety, tolerability, efficacy and mechanism of action are still required. Notes the 2011 voluntary withdrawal of Danzen/Dasen serratiopeptidase tablets in Japan after failure to show efficacy superior to placebo. No osteoarthritis-specific efficacy data presented.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
Products may be legally marketed as dietary supplements if claims about diagnosis, cure, mitigation, treatment, or prevention are removed from promotional materials and the products otherwise comply with all applicable provisions of the Act and FDA regulations. source↗
L4b EU EFSA
Against
L4c UK NHS
Against
Serratiopeptidase is an unauthorised novel food, and it is illegal for businesses to sell serrapeptase as a food supplement for human consumption in the EU and UK because it is an unauthorised novel food. source↗
L4d TW TFDA / 衛福部
Neutral
適應症：手術後及外傷後之消炎、副鼻腔炎、膀胱炎、副睪丸炎、智齒周圍炎、齒槽膿瘍之消炎、支氣管炎。 source↗
L5a NIH Office of Dietary Supplements
Cautious